One from Europe and two from Eurasia
Suven Life Sciences announced that it has been granted one (1) product patent from Europe (2507225) and two (2) product patents from Eurasia (023293 and 023260) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2029, 2030 and 2031 respectively.With these new patents, Suven has a total of twenty one (21) granted patents from Europe and Nineteen (19) granted patents from Eurasia. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out]licensed at various phases of clinical development like at Phase]I or Phase]II.
Powered by Capital Market - Live News